Form 4: Moderna Director Noubar Afeyan Receives Stock Options

Moderna, Inc. director Noubar Afeyan was granted 12,908 stock options as part of standard equity compensation.

Summary

• Director Noubar Afeyan received a grant of 12,908 stock options for Moderna, Inc. (MRNA) common stock.
• The options have an exercise price of $48.79 per share.
• The grant date for these options is May 6, 2026.
• The options are set to expire on May 6, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance or outlook.

Positives

• The grant aligns the director's long-term interests with those of shareholders through equity-based compensation.

Negatives

• The issuance of new stock options results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is subject to market volatility and the future performance of Moderna's stock price.

Future Outlook

The options vest on the earlier of May 6, 2027, or the company's next Annual Meeting of Shareholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure alignment between board members and long-term company performance.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with compensation practices at other large-cap pharmaceutical and biotech firms like Pfizer, Amgen, and Gilead Sciences.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 6, 2027, or the next Annual Meeting of Shareholders.

Key Dates

Keywords

Moderna, MRNA, Director, Stock Options, Insider Trading, Equity Compensation